MarketWatch.com - Top Stories

Sarepta Therapeutics’ stock falls after patient dies of liver failure

The company said that more than 800 people have been treated with Elevidys, with only one experiencing liver failure.

Mar 18, 2025 - 14:58
 0
Sarepta Therapeutics’ stock falls after patient dies of liver failure
The company said that more than 800 people have been treated with Elevidys, with only one experiencing liver failure.
Read More

Tags:

Previous Article

Households plans for long-term care, but those plans may not reflect reality

Next Article

Prediction: These 2 Stocks Will Outperform the Market Through 2030

Related Posts

Intuitive Machines’ second moon lander has run into problems. The stock is sliding.

Intuitive Machines’ second moon lander has run into pro...

Mar 6, 2025  0

Biogen’s stock slides on soft guidance and a decline in sales of MS drugs

Biogen’s stock slides on soft guidance and a decline in...

Feb 12, 2025  0

Why it pays to keep your political opinions away from your money

Why it pays to keep your political opinions away from y...

Mar 6, 2025  0